Acyclovir

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1982

www.ebi.ac.uk

First approval year: 1982
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Acyclovir
www.ebi.ac.uk

Molecular weight: 225.21
www.ebi.ac.uk

Structure (SMILES): Nc1nc2c(ncn2COCCO)c(=O)[nH]1
www.ebi.ac.uk

acycloguanosine
Acycloguanosine
acyclovir
Acyclovir
acyclovir component of xerese
Acyclovir component of xerese
avaclyr
Avaclyr
avert
Avert
clearsore
Clearsore
cymex ultra
Cymex ultra
duvimex
Duvimex
herpetad
Herpetad
lipsore
Lipsore
lypsyl
Lypsyl
ranovir
Ranovir
sitavig

And 17 more, listed on the interactive page.

aciclovir
Aciclovir
ACICLOVIR [EP MONOGRAPH]
ACICLOVIR [IARC]
aciclovir [INN]
ACICLOVIR [JAN]
ACICLOVIR [MART.]
Aciclovir [WHO-DD]
ACICLOVIR [WHO-IP]
aciclovir ep monograph
aciclovir iarc
aciclovir inn
aciclovir jan
aciclovir mart
aciclovir who dd
aciclovir who ip
aciclovirum
Aciclovirum
ACICLOVIRUM [WHO-IP]
aciclovirum who ip
acyclovir
Acyclovir
ACYCLOVIR [HSDB]
ACYCLOVIR [MI]
ACYCLOVIR [ORANGE BOOK]

And 23 more, listed on the interactive page.

CAS registry numbers

59277-89-3

ChEMBL ID: CHEMBL184
www.ebi.ac.uk

InChIKey: MKUXAQIIEYXACX-UHFFFAOYSA-N
www.ebi.ac.uk

PubChem compound IDs

135398513

RxNorm IDs (RxCUI)

FDA ingredient codes (UNII)

X4HES1O11F

D06BB03
D06BB53
J05AB01
S01AD03

Sources for recorded values

www.ebi.ac.uk

Applicant: BAUSCH
Approval date: 29 Mar 1982
Application number: NDA018604

Patents: 3
Designations: 2
Earliest recorded loss of exclusivity: 16 Jun 2030
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only

Pharmacology name: aciclovir
Type: Synthetic organic
Drug name stem: -vir
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral
Parenteral
topical

Mechanisms of action

Mechanism
Human herpesvirus 1 DNA polymerase inhibitor
Action type
Inhibitor
Target
DNA polymerase catalytic subunit
Protein identifier
P04293

Open Targets mechanisms

Mechanism
Human herpesvirus 1 DNA polymerase inhibitor
Action type
Inhibitor
Target
DNA polymerase catalytic subunit

Action type
Inhibitor
Protein identifier
P04293
Organism
Human herpesvirus 1 (strain 17)
Action type
Inhibitor
Gene symbol
TK
Protein identifier
P04407
Organism
Human herpesvirus 2 (strain 333)
Action type
Inhibitor
Protein identifier
P09252
Organism
Varicella-zoster virus (strain Dumas)
Action type
Inhibitor
Gene symbol
TK
Protein identifier
Q9QNF7
Organism
Human herpesvirus 1

Condition
Virus Diseases
Highest recorded phase
4
Condition identifier
EFO:0000763
Subject identifier
D014777
Condition
HIV Infections
Highest recorded phase
3
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Cytomegalovirus Infections
Highest recorded phase
3
Condition identifier
EFO:0001062
Subject identifier
D003586
Condition
Herpes Zoster
Highest recorded phase
4
Condition identifier
EFO:0006510
Subject identifier
D006562
Condition
Chickenpox
Highest recorded phase
4
Condition identifier
EFO:0007204
Subject identifier
D002644
Condition
Herpes Genitalis
Highest recorded phase
4
Condition identifier
EFO:0007282
Subject identifier
D006558
Condition
Herpes Labialis
Highest recorded phase
4
Condition identifier
EFO:1001347
Subject identifier
D006560
Condition
Eye Infections
Highest recorded phase
4
Condition identifier
EFO:1001888
Subject identifier
D015817
Condition
Herpes Simplex
Highest recorded phase
4
Condition identifier
EFO:1002022
Subject identifier
D006561
Condition
Herpes Labialis
Highest recorded phase
4
Condition identifier
MONDO:0043653
Subject identifier
D006560

Condition identifier
EFO_0000763
Condition identifier
EFO_0000764
Highest recorded phase
3
Condition identifier
EFO_0001062
Highest recorded phase
3
Condition identifier
EFO_0004352
Condition identifier
EFO_0006510
Condition identifier
EFO_0007204
Condition identifier
EFO_0007282
Condition identifier
EFO_0007309
Condition identifier
EFO_1001231
Condition identifier
EFO_1001360
Condition identifier
EFO_1001888
Condition identifier
EFO_1001888
Highest recorded phase
4
Condition identifier
EFO_1002022
Condition identifier
EFO_1002023
Condition identifier
HP_0010628
Condition identifier
MONDO_0000878
Condition identifier
MONDO_0001795
Highest recorded phase
2
Condition identifier
MONDO_0004609
Highest recorded phase
4
Condition identifier
MONDO_0004992
Highest recorded phase
2
Condition identifier
MONDO_0005108
Highest recorded phase
4
Condition identifier
MONDO_0005609
Highest recorded phase
4
Condition identifier
MONDO_0005665
Condition identifier
MONDO_0005700
Highest recorded phase
4
Condition identifier
MONDO_0005770
Highest recorded phase
4
Condition identifier
MONDO_0005855

And 9 more, listed on the interactive page.

Event
acute generalised exanthematous pustulosis
Reports
91
Reporting signal score
167.423
Event
acute kidney injury
Reports
599
Reporting signal score
781.848
Event
altered state of consciousness
Reports
97
Reporting signal score
122.98
Event
blood creatinine increased
Reports
186
Reporting signal score
171.264
Event
blood urea increased
Reports
74
Reporting signal score
91.1867
Event
confusional state
Reports
277
Reporting signal score
197.647
Event
crystal urine present
Reports
35
Reporting signal score
123.368
Event
crystalluria
Reports
46
Reporting signal score
176.895
Event
depressed level of consciousness
Reports
108
Reporting signal score
89.663
Event
dilatation intrahepatic duct acquired
Reports
27
Reporting signal score
110.862
Event
disorientation
Reports
105
Reporting signal score
99.6363
Event
drug reaction with eosinophilia and systemic symptoms
Reports
113
Reporting signal score
121.092
Event
drug resistance
Reports
173
Reporting signal score
281.271
Event
encephalitis
Reports
60
Reporting signal score
119.703
Event
encephalopathy
Reports
159
Reporting signal score
244.531
Event
hallucination, visual
Reports
86
Reporting signal score
110.576
Event
herpes simplex
Reports
83
Reporting signal score
202.304
Event
lymphocyte count decreased
Reports
83
Reporting signal score
97.2768
Event
myoclonus
Reports
80
Reporting signal score
120.141
Event
nephropathy toxic
Reports
143
Reporting signal score
302.922
Event
neurotoxicity
Reports
324
Reporting signal score
812.112
Event
ophthalmic herpes simplex
Reports
25
Reporting signal score
86.1935
Event
organic brain syndrome
Reports
22
Reporting signal score
97.1394
Event
pathogen resistance
Reports
153
Reporting signal score
381.029
Event
rash maculo-papular
Reports
111
Reporting signal score
131.121

And 12 more, listed on the interactive page.

NCT00194519
clinicaltrials.gov
NCT01281007
clinicaltrials.gov
NCT00467662
clinicaltrials.gov
NCT00469300
clinicaltrials.gov
NCT00769314
clinicaltrials.gov
NCT01574612
clinicaltrials.gov
NCT02265913
clinicaltrials.gov
NCT02483182
clinicaltrials.gov
NCT01327144
clinicaltrials.gov
NCT03443869
clinicaltrials.gov

Dose: Approximate a one-half inch ribbon of ointment per 4 square inches of surface area
Route: Topical
How often: Every 3 hours, 6 times per day for 7 days

Conditions of use

Use a finger cot or rubber glove during application

Hydrogen bond acceptors: 7
Hydrogen bond donors: 3
Polar surface area: 119.05
Calculated partition coefficient (ALogP): -1.33
Calculated partition coefficient (XLogP): -1.9
Prodrug: Yes
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 4
Heavy atoms: 16
Molecular formula: C8H11N5O3
Monoisotopic mass: 225.08618923
Natural product: Yes

0093-3630
0187-0993
0187-0994
0187-5104
0472-0082
0591-1159
0904-7507
0904-7519
13668-515
16714-885
23155-227
23155-228
23155-229
23155-962
31722-681
31722-777
31722-778
33342-439
43063-589
43063-928
43547-499
45802-044
48102-028
50268-061
50268-062

And 163 more, listed on the interactive page.

Recorded assays: 8,599
Active assays: 563

Confirmatory
Other
Screening
Summary

Antiviral Agents
id.nlm.nih.gov

Distribution coefficient (LogD)

Median: -2
Mean: -2
Minimum: -2
Maximum: -2
Unit: unitless
Assays: 1
Standard deviation: 0
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

LogD

Solubility

Median: 1,895
Mean: 2,177.5
Minimum: 1,000
Maximum: 3,920
Unit: ug/mL
Assays: 4
Standard deviation: 1,330.97
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Solubility

Oral bioavailability

Median: 48
Mean: 37.8808
Minimum: 2.8
Maximum: 83
Unit: %
Assays: 13
Standard deviation: 27.72
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Related records

Trials (96)

A Clinical Trial of Acyclovir for Viral Uveitis
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand
A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Aciclovir Versus Placebo for HSV-2 Meningitis
Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates
Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth

Approved for (7)

In development for (2)

Cytomegalovirus infection Phase 3
HIV infectious disease Phase 3

Acyclovir

Development status

Names and chemistry

Brand names (42)

Other names (48)

Identifiers

ATC classification codes (4)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action

Open Targets mechanisms

DrugCentral mechanisms (4)

Investigated indications (10)

Open Targets indications (34)

Reported adverse events (37)

Trial references (10)

Dosing

Conditions of use

Chemical properties

National Drug Codes

Evidence counts

Active assay types (4)

Pharmacologic actions

Biological measurements

Observed measurements

Distribution coefficient (LogD)

Measurement types

Solubility

Measurement types

Oral bioavailability

Measurement types

Related records

Trials (96)

Approved for (7)

In development for (2)

Other linked conditions (3)